Prabhakar Baliga to Combined Modality Therapy
This is a "connection" page, showing publications Prabhakar Baliga has written about Combined Modality Therapy.
Connection Strength
0.038
-
Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
Score: 0.031
-
Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Transplant Proc. 1995 Oct; 27(5 Suppl 1):42-3.
Score: 0.007